Haplotype-specific PCR for NAT2 diplotyping

Nuanjun Wichukchinda1, Jirapa Pakdee1, Punna Kunhapan1, Wimala Imunchot1, Licht Toyo-oka2,3, Katsushi Tokunaga2,4 and Surakameth Mahasirimongkol1

Abstract

N-acetyltransferase 2 (NAT2) is an enzyme that acetylates many kinds of drugs, including the antituberculosis drug isoniazid. The NAT2 gene is highly diverse across populations. An individual can be classified as having a slow acetylator (SA), an intermediate acetylator (IA), or a rapid acetylator (RA) phenotype based on its two haplotypes (diplotype) of NAT2. SA individuals are at a higher risk for isoniazid-induced hepatitis, while the RA phenotype contributes to failure in tuberculosis treatment. Being able to predict individual NAT2 phenotypes is important for dose adjustment of isoniazid. NAT2 haplotypes are commonly determined via an indirect method of statistical haplotype inference from SNP genotyping. Here, we report a direct NAT2 haplotyping method using haplotype-specific PCR (HS-PCR) for the 6 most commonly found NAT2 haplotypes: NAT2*4, NAT2*5B, NAT2*6A, NAT2*7B, NAT2*12A, and NAT2*13A. Validation of this HS-PCR method via comparison with a sequencing method in 650 Thai DNA samples (107 RA, 279 IA, and 264 SA samples) showed a concordance rate for diplotype calls of 99.23% (645/650 samples). The discordant results in 5 samples were due to 3 rare NAT2 haplotypes: NAT*5C (n = 3), NAT*7C (n = 1), and NAT2*11A (n = 1). This novel HS-PCR method allows direct NAT2 diplotyping, enabling the implementation of NAT2 acetylator phenotypes in clinical pharmacogenetic testing.

Introduction

N-acetyltransferase 2 (NAT2) is a liver enzyme necessary for the detoxification and metabolism of foreign chemicals and various drugs, such as caffeine, isoniazid, sulfamidine, hydrazine, dapsone, procaine amide, sulfapyridine, and nitrazepam1–4. The NAT2 gene is highly diverse, with 20 clusters (108 haplotypes) reported in the global population1,5. NAT2*4 is considered the reference and encodes a high-enzymatic activity product. The other NAT2 haplotypes are assigned according to their SNP variances in exon 2.5. Haplotype inference is usually derived from the seven most common SNPs, namely, rs1801279 (191G > A), rs1041983 (282C > T), rs1801280 (341T > C), rs1799929 (481C > T), rs19817930 (590G > A), rs1208 (803A > G), and rs1799931 (857G > A), which are the signature SNPs for the following 7 clusters: NAT2*14, NAT2*13, NAT2*5, NAT2*11, NAT2*6, NAT2*12, and NAT2*7, respectively. NAT2 haplotypes containing the nonsynonymous SNPs 191G > A (R64Q), 341T > C (I114T), 590G > A (R197Q), and 857G > A (K268R) encode low-activity or slow acetylation enzymes. Common slow acetylation haplotypes include NAT2*5B, NAT2*6A, NAT2*7B, and NAT2*14A/*14B, whereas NAT2*12A and NAT2*13A encode high-activity enzymes similar to those from reference NAT2*4.5 According to the codominance of two NAT2 haplotypes (diplotype), individual phenotypes are classified as rapid acetylator (RA), intermediate acetylator (IA), or slow acetylator (SA). The distribution of NAT2 haplotypes and the proportions of SA, IA, and RA vary among ethnic groups.5

Tuberculosis (TB) is one of the most serious health problems, with more than 2 billion infected people (approximately one-third of the world’s population) and an estimated 10 million new cases occurring in 2017.6 In
Thailand, more than 100,000 patients have been diagnosed with TB, and 12,000 die every year\textsuperscript{7}; hence, precise diagnosis and treatment are necessary to control TB. Anti-TB drugs are usually combined drugs that are administered for a 2-month period. The first-line anti-TB drug is composed of isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin. The most common adverse reaction to anti-TB drugs is skin rash (15.4%); hepatitis is the second most common (9.2%) adverse effect, but it is more life-threatening than skin rash and causes treatment failure\textsuperscript{8,9}.

Patients with the SA phenotype are prone to adverse effects from drugs metabolized by NAT2. A meta-analysis that included 14 studies\textsuperscript{10} showed that the risk of anti-TB drug-induced liver injury (AT-DILI) was higher for the SA type than for other acetylator types (OR = 4.695, 95% CI: 3.291–6.705, \( p < 0.001 \)). This finding was confirmed in a study of the Thai population\textsuperscript{11} that also explored AT-DILI (OR = 8.80, 95% CI: 4.01–19.31, \( p = 1.53 \times 10^{-8} \)). Therefore, being able to determine a patient’s NAT2 acetylator type would help physicians adjust the dosage of isoniazid.

NAT2 haplotypes are conventionally determined by inference from seven common SNPs located in exon 2 of the NAT2 gene. SNP genotyping methods, such as sequencing\textsuperscript{12}, real-time polymerase chain reaction (PCR)\textsuperscript{13}, PCR-restriction fragment length polymorphism\textsuperscript{14,15}, allele-specific sequencing\textsuperscript{16}, and allele-specific primer extension\textsuperscript{17}, have complicated steps, are laborious, time-consuming and costly, and/or require sophisticated machines. These resource requirements limit the routine use of such methods in clinical applications. Furthermore, statistical inference may be error-prone and difficult for nonstatisticians to conduct. Therefore, we aimed to develop a simple and low-cost method for NAT2 diplotyping that directly provides 2 haplotypes without an inference step and can therefore be used in routine service.

**Materials and methods**

Frozen EDTA blood samples (\( n = 650 \)) from stocks available from the Third Thailand National Health Examination Survey Program were randomly selected to represent the Thai populations of 13 health areas. The survey was approved by the Ethical Review Committee for Research in Human Subjects, Ministry of Public Health\textsuperscript{18}, and all participants provided written informed consent. We obtained permission to use these frozen blood samples with information on sex and residential area. DNA samples were extracted using a commercial kit (QIAamp DNA blood mini kit, QIAGEN GmbH, Germany) and quantitated using a spectrophotometer (Nanodrop-100, Wilmington, DE 19810, USA).

The haplotype-specific PCR-based method (HS-PCR) for NAT2 diplotyping presented here uses 6 reaction tubes, with each tube containing a specific primer pair for one of the haplotypes most commonly found in Thai populations (NAT2*4, NAT2*5B, NAT2*6A, NAT2*7B, NAT2*12A, and NAT2*13A). These oligonucleotide primers were designed using NAT2*4 (NG_012246.1 *Homo sapiens* N-acetyltransferase 2 (NAT2), RefSeqGene on chromosome 8) as a reference sequence. Specific amplification of only one NAT2 haplotype was performed by using a combination of forward and reverse primers that contained a haplotype signature SNP as the last base at the 3′ end of the oligonucleotide primer, and its paired primer also contained a specific base at the 3′ end. The six variant bases of these six common NAT2 haplotypes and the last 3′ end base of each primer are provided in Table 1. Since primers with only a single 3′ mismatched base may give false-positive results, the amplification refractory mutation system\textsuperscript{19,20} was used to introduce an additional mismatched base at the −2 position from the 3′ end of the primer to increase the specificity of HS-PCR. A primer pair (TIMP1-Fw/TIMP1-Rv) for amplification of *TIMP1*, a gene located on chromosome X, was used as an internal

**Table 1 The 7 most common SNPs in NAT2 exon 2.**

| SNP position | NAT2 haplotype   | 191   | 282   | 341   | 481   | 590   | 803   | 857   |
|--------------|------------------|-------|-------|-------|-------|-------|-------|-------|
| rs1801279    | NAT2*4           | G     | C     | T     | C     | G     | A     | G     |
| rs1041893    | NAT2*5B          | G     | C     | C     | T     | G     | G     | G     |
| rs1801280    | NAT2*6A          | G     | T     | T     | C     | A     | A     | G     |
| rs199929     | NAT2*7B          | G     | T     | T     | C     | G     | A     | A     |
| Rs1799930    | NAT2*12A         | G     | C     | T     | C     | G     | G     | G     |
| rs1208       | NAT2*13A         | G     | T     | T     | C     | A     | A     | G     |
| rs1799931    |                  |       |       |       |       |       |       |       |

*Indicates the signature SNP for each NAT2 cluster. *Fw* indicates the last base at the 3′ end of the forward primer, and *Rv* indicates the last base at the 3′ end of the reverse primer. SNP positions were identified by designating “K” of the “ATG” start codon as the first position.
control in every reaction tube. The primer sequences used to amplify specific NAT2 haplotypes and TIMP1 and the amplified product sizes are shown in Table 2. The final PCR (12 μl) was composed of 1X ready mix reagent (KAPA2G Fast Multiplex Mix, KAPA Biosystems, Boston, Massachusetts, USA), the NAT2-specific primer pair (0.3 μM), the TIMP1 primer pair (0.1 μM), and 20–50 ng of a DNA sample. After denaturation at 95 °C for 5 min, 35 cycles of amplification (95 °C for 20 s, 65 °C for 20 s, and 72 °C for 30 s) were performed. The primer sequences used to amplify specific NAT2 haplotypes and TIMP1 and the amplified product sizes are shown in Table 2. The six NAT2 haplotypes were directly determined by evaluating the specific sizes of the PCR products in 1.5% agarose gels stained with ethidium bromide.

For NAT2 direct sequencing, the PCR-Fw/PCR-Rv primer pair (shown in Table 2) was used to amplify the whole exon 2 of NAT2. A 10-μl PCR containing 1X KAPA2G Fast Multiplex Mix, 0.2 μM each primer, and 10–20 ng of DNA was performed under the following conditions: 95 °C for 5 min and 35 cycles at 95 °C for 20 s, 65 °C for 15 s, and 72 °C for 60 s. The amplified products were treated with exonuclease I and alkaline phosphatase (Illustra ExoProStar, GE Healthcare UK Ltd., Buckinghamshire, England) at 37 °C for 30 min and then 95 °C for 15 min to remove unincorporated primers and dNTPs. The sequencing reactions were performed by using 1 ml of the treated PCR products, sequencing primers (shown in Table 2), and a 1X BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). After purification (D-PureTM Dye Terminator Removal Kit, NimaGen BV, Nimagen, NL), the sequences were read by a 3500XL genetic analyzer (Applied Biosystems). The variants in exon 2 of NAT2 were called by Variant ReporterTM Software v2 (Applied Biosystems). The NAT2 haplotype was inferred based on the most common 7 SNP positions using PHASE software21,22.

### Acetylator phenotype interpretation

Since each individual carried two haplotypes (diplotype) in a codominant fashion, analysis of the relationships between NAT2 diplotypes and acetylator phenotypes was performed as follows. Homozygous or heterozygous genotypes among fast NAT2 haplotypes (NAT2*4/*4, NAT2*4/*12A, NAT2*4/*13A, NAT2*12A/*12A, NAT2*12A/*13A, and NAT2*13A/*13A) were interpreted as RAs. Homozygous or heterozygous genotypes among slow NAT2 haplotypes (NAT2*5B/*5B, NAT2*5B/*6A, NAT2*5B/*7B, NAT2*6A/*6A, NAT2*6A/*7B, and NAT2*7B/*7B) were interpreted as SAs. Heterozygous genotypes between fast

---

**Table 2 Primers and sequences used in NAT2 haplotype-specific PCR and direct sequencing.**

| NAT2 haplotype | Primer name | bp | 5′-3′ sequence | PCR product (bp) |
|----------------|-------------|----|----------------|-----------------|
| NAT2*4         | 4F-282C     | 36 | GGT TTT CAG ACC ACA ATG TTA GGA GGG TAT TTT GAC | 588             |
| NAT2*4         | 4R-803A     | 38 | CAC GAG ATT TCT CTC CCA GAA GAT CCT AAT ATG TT  |                 |
| NAT2*5B        | 5F-341C     | 30 | CAT GGT TCA CCT TCT CCT GCA GGT GAC AAC         | 582             |
| NAT2*5B        | 5R-857G     | 35 | TTT ATT TTG TTC ATT CTA AAT AGT AGG GCC TC      |                 |
| NAT2*5B        | 6F-341T     | 22 | ACC TTC TCC TGC AGG TGA CAA T                  | 300             |
| NAT2*5B        | 6R-590A     | 28 | TTC ATA GAC TCA AAA TCT TCA ATT GGT T          |                 |
| NAT2*6A        | 7F-481C     | 26 | GAC AGA AGA GAG AGG AAT CTG GTG CTG CC         | 431             |
| NAT2*7B        | 7R-857A     | 35 | TTT ATT TTG TTC ATT CTA AAT AGT AGG GCC TT     |                 |
| NAT2*7B        | 12F-481C    | 26 | GAC AGA AGA GAG AAT CTG GTC CC                 | 387             |
| NAT2*12A       | 12R-803G    | 38 | CAC GAG ATT TCT CTC CCA GAA GAT CCT AAT ATG TC |                 |
| NAT2*12A       | 13F-282T    | 29 | AGA CCA CAA TGT TAG GAG GGT ATT TTG AT         |                 |
| NAT2*13A       | 13R1-590G   | 28 | TTC ATA GAC TCA AAA TCT TCA ATT GGT C          | 366             |
| NAT2*13A       | 13R2-857G   | 36 | GGT TAT TTT GTT CCT TAT AAA TAG TAA GGG TTC    | 641             |
| TIMP1          | TIMP1-F     | 29 | AGT TTC TCA TTG CTG AGG CAC GTG CC             | 817             |
| TIMP1          | TIMP1-R     | 29 | AGC CAT CAG GGA ACA GCC TTG GAC TAG CC         |                 |
| NAT2-Exon2     | PCR-Fw      | 23 | CAT GTA AAA GGG ATT CAT GCA GT                 | 1315            |
|               | PCR-Rv      | 23 | TAG CAT GAA TCA CTC TGA TTC CC                |                 |
|               | Seq-Fw      | 25 | CAG GTC AAT CAA CTG TAC TGG G                 |                 |
|               | Seq-Rv      | 29 | GCA CAT AAG TTG ATA ATT AGT GAG TTG GG        |                 |
and slow NAT2 haplotypes (NAT2*4/*5B, NAT2*4/*6A, NAT2*4/*7B, NAT2*5B/*12A, NAT2*5B/*13A, NAT2*6A/*12A, NAT2*6A/*13A, NAT2*7B/*12A, and NAT2*7B/*13A) were interpreted as IAs.

Results

Direct NAT2 diplotyping by HS-PCR

A novel method for genotyping NAT2 diplotypes was developed using NAT2 HS-PCR. The detection range of this method is 5–200 ng of DNA (data not shown). For each NAT2 haplotype, the specific amplified product size can be clearly and directly observed under UV light after agarose gel electrophoresis and Et–Br staining (Fig. 1). Each NAT2-haplotype reaction tube produces a specific band when a sample is positive for that particular haplotype, except for the NAT2*13 reaction tube, which produces 2 bands of 366 bp and 641 bp from one forward primer and 2 reverse primers. The concordance rate for diplotyping between the novel HS-PCR method and the indirect sequencing method among 650 DNA samples was 99.23% (645/650). The discordant results observed for five samples were due to rare NAT2 haplotypes comprising NAT2*5C (three samples), NAT2*7C (1 sample), and NAT2*11A (1 sample), which were designated NAT2*5B, NAT2*7B, and NAT2*4 by HS-PCR, respectively. However, in all 650 samples, the interpretation of acetylator phenotypes from NAT2 diplotypes by the HS-PCR method was 100% concordant with that from the direct sequencing method.

Frequency of NAT2 haplotypes and acetylator phenotypes in the Thai population

The NAT2 haplotypes found by Sanger sequencing and haplotype inference in 650 samples randomly selected from a nationwide Thailand population confirmed that the 6 most common haplotypes (from highest to lowest frequency) were NAT2*4 (35.46%), NAT2*5B (9.77%), NAT2*6A (33.85%), NAT2*7B (18.15%), NAT2*12A (0.62%), and NAT2*13A (1.77%). Three rare haplotypes (NAT2*5C (0.23%), *7C (0.08%), and *11A (0.08%)) were also found. The frequencies and 95% CIs of these nine NAT2 haplotypes are shown in Table 3, demonstrating that NAT2*4 and NAT2*6B were the most common, occurring at nearly the same frequency. Interpretation of acetylator phenotypes revealed that the frequencies of acetylator types in the Thai population were 0.165 [0.136–0.193] for RAs, 0.429 [0.391–0.467] for IAs, and 0.406 [0.368–0.444] for SAs.

Discussion

A novel method was developed for direct genotyping of NAT2 diplootypes using haplotype-specific primers to amplify 6 common NAT2 haplotypes (NAT2*4, *5B, *6A, *7B, *12A, and *13A) found in a non-African population, i.e., the Thai population⁵. In this method, TIMP1 amplification was used as an internal control to safeguard against false negatives from failure of the PCR experiment due to the reaction mix, thermal cycler, or DNA sample. When this 817-bp product is absent from any HS-PCR reaction tube, that sample should be interpreted as having an indeterminate result and retested. This quality-control step ensures that homozygote diplootype calls obtained using HS-PCR are not caused by the failure to amplify another haplotype.

A validation method showed that this HS-PCR technique for NAT2 diplotyping provided perfect concordance of acetylator phenotype interpretation (107 RAs, 279 IAs, and 264 SAs) with the results of the reference sequencing method.

The three discordant haplotyping results between the sequencing method and this HS-PCR method were NAT2*5C vs. NAT2*5B (n = 3), NAT2*7C vs. NAT2*7B (n = 1), and NAT2*11A vs. NAT2*4 (n = 1). Since NAT2*5C, NAT2*5B, NAT2*7C, and NAT2*7B are slow acetylator haplotypes and NAT2*11A is a fast acetylator haplotype, interpretation of the phenotypes for these five cases was not changed, as follows: two cases of the IA type (NAT2*4/*5C = NAT2*4/*5B and NAT2*5C/*13A = NAT2*5C/*13A), two cases of the SA type (NAT2*6A/*7C = NAT2*6A/*7B and NAT2*5C/*7B = NAT2*5B/*7B), and one case of the FA type (NAT2*4/*11A = NAT2*4/*4).

Because this method provides 2 individual haplotypes, it is very useful for adjusting acetylator phenotypes to alternative classifications according to new findings. For
example, \textit{NAT2}^*/SB, \textit{NAT2}^*/6A, and \textit{NAT2}^*/7B are suggested to be slow acetylator haplotypes, whereas \textit{NAT2}^*/6A, \textit{NAT2}^*/7B, and \textit{NAT2}^*/7B are ultra slow acetylator haplotypes associated with DILI. In this study, the \textit{NAT2} haplotypes detected by Sanger sequencing and haplotype inference in 650 samples randomly selected from a nationwide Thailand population confirmed the pattern of the 6 most commonly found haplotypes (\textit{*4}, \textit{*6B}, and \textit{*7A} at a higher frequency and \textit{*5}, \textit{*12A}, and \textit{*13A} at a lower frequency) as being similar to those previously reported in a northeastern Thai sample (\textit{n} = 235 individuals). Our study found a lower frequency of \textit{*5} but a higher frequency of \textit{*13} compared with those in the study by Kulkongviriyapan et al. (\textit{p} < 0.05). However, compared with Sabbagh et al. (\textit{n} = 44 Thai individuals), we did not find significant differences in the frequencies of \textit{*4}, \textit{*5B}, \textit{*6A}, \textit{*7B}, and \textit{*13}. The interpretation of SA phenotypes was not different between our findings and those of Kulkongviriyapan et al. (0.406 (0.368–0.444) vs. 0.362 (0.300–0.423), respectively).

As of April 2016, 108 \textit{NAT2} haplotypes grouped into 20 clusters were recorded. A member of a \textit{NAT2}-haplotype cluster will have a cluster-signature SNP plus other SNPs. A cluster consisting of \textit{*5}–\textit{*7} and \textit{*11}–\textit{*14} corresponds to members with more than 1 haplotype, while the rest are rarely found. This novel HS-PCR method for \textit{NAT2} diplotyping does not cover the \textit{NAT2}^*/14 cluster found in African populations; therefore, it cannot be used in such populations.

Since this method was developed based on the six most common \textit{NAT2} haplotypes, other uncommon haplotypes cannot be clearly determined and may be misclassified. The haplotypes that can potentially be amplified by each of the six specific \textit{NAT2}-haplotype reaction tubes are shown in supplement 1. However, the misclassifications that we observed in the Thai population were mostly within the same cluster and/or shared the same acetylator phenotype, such that clinical recommendations were unchanged. Some DNA samples with rarer \textit{NAT2} haplotypes may generate unusual band patterns or show more than two haplotypes. In these cases, the DNA sample should be checked for possible cross-contamination at the DNA extraction or PCR step. If the result remains uninterpretable, the sample should be subjected to Sanger sequencing.

**Conclusion**

This method involves direct \textit{NAT2} diplotyping, has no risk of errors caused by statistical haplotype inference, and can be implemented in a simple molecular laboratory with a lower cost and shorter turnaround time than those for other methods. This novel HS-PCR method is the first step toward enabling the routine use of \textit{NAT2} acetylator status as an indicator in clinical practice.

**Disclaimer**

A patent has been filed for the primer set designed/developed in this study in Thailand (No. 1601001130) and internationally (PCT/TH2017/000014).

**Acknowledgements**

This study was supported by the Department of Medical Sciences, the Ministry of Public Health, Thailand, and the Japan Agency for Medical Research and Development/Japan International Cooperation Agency under the Science and Technology Research Partnership for Sustainable Development (SATREPS) project (Grant no. JP18jmi011001). We thank the Health Systems Research Institute, Thailand, and the National Health Security Office for allowing us to use frozen blood samples obtained during the Third NHES program, which was supported by the Bureau of Policy and Strategy, Ministry of Public Health, Thailand.

**Table 3 Distribution of \textit{NAT2} haplotypes in the Thai population (\textit{n} = 650).**

| \textit{NAT2} haplotype 2 | \textit{NAT2} haplotype | Frequency | 95% CI |
|---------------------------|-------------------------|----------|-------|
| \*4 | \*5B | \*5C | \*6A | \*7B | \*7C | \*11A | \*12A | \*13A | \textbf{n} |          |          |
| 93 | 44 | 1 | 139 | 78 | 0 | 1 | 3 | 9 | 461 | 0.355 | 0.329–0.381 |
| 8 | 0 | 43 | 24 | 0 | 0 | 0 | 0 | 0 | 127 | 0.098 | 0.082–0.115 |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 0.002 | 0.000–0.007 |
| 88 | 73 | 1 | 0 | 2 | 6 | 440 | 0.338 | 0.313–0.365 |
| 0 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 236 | 0.182 | 0.161–0.204 |
| 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0.006 | 0.003–0.012 |
| 0 | 0 | 0 | 0 | 1 | 0.001 | 0.000–0.004 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.001 | 0.000–0.004 |
| 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0.006 | 0.003–0.012 |
Author details
1Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand. 2Department of Human Genetics, Graduates School of Medicine, The University of Tokyo, Tokyo, Japan. 3Present address: National Bioscience Database Center, Japan Science and Technology Agency, Tokyo, Japan.

Conflict of interest
The authors declare that they have no Conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
is available for this paper at https://doi.org/10.1038/s41439-020-0101-7.

Received: 16 October 2019 Accepted: 1 April 2020.
Published online: 11 May 2020

References
1. Blum, M., Grant, D. M., McBride, W., Heim, M. & Meyer, U. A. Human arylamine N-acetyltransferase 2 gene: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9, 193–203 (1990).
2. Boukouvala S. Human NAT2 Alleles (Haplotype). http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm (2019).
3. Sim, E., Abuhammad, A. & Ryan, A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br. J. Pharm. 171, 2705–2725 (2014).
4. Butcher, N. J., Boukouvala, S., Sim, E. & Minchin, R. F. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenom. J 2, 30–42 (2002).
5. Sabbagh, A., Darlu, P., Crouau-Roy, B. & Poloni, E. S. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PloS ONE 6, e18507 (2011).
6. World Health Organization. Global Tuberculosis Report 2018 http://www.who.int/tb/publications/global_report/en/ (2018).
7. Ministry of Public Health, Thailand. Thailand Operational Plan to End Tuberculosis 2017–2027. https://tbthailand.org/download/Manual/Thailand%20Operational%20Plan%20To%20End%20TB%202017_2021.pdf (2018).
8. Huang, Y. S. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J. Chin. Med. Assoc. 77, 169–173 (2014).
9. Huang, Y. S. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 3, 1–8 (2007).
10. Wang, P. Y., Xie, S. Y., Hao, Q., Zhang, C. & Liang, B. F. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J. Tuberc. Lung Dis. 16, 589–595 (2012).
11. Wattanapokanyak, S. et al. NAT2 slow acetylator associated with antituberculosis drug-induced liver injury in Thai patients. Int. J. Tuberc. Lung Dis. 20, 1364–1369 (2016).
12. Agundez, J. A. et al. Unraveling ambiguous NAT2 genotyping data. Clin. Chem. 54, 1390–1394 (2008).
13. Hein, D. W. & Doll, M. A. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 13, 31–41 (2012).
14. Oqal, M. K., Mustafa, K. N. & Irshaid, Y. M. N-acetyltransferase-2 genotypes among patients with rheumatoid arthritis attending Jordan University Hospital. Genet Test. Mol. Biomark. 16, 1007–1010 (2012).
15. Jarrar, Y. B., Balasmeh, A. A. & Jarrar, W. Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers. J.byn J. Med. 13, 1408B81 (2018).
16. Kang, S. H., Park, G., Jang, S. J. & Moon, D. S. Novel NAT2 haplotyping using allele-specific sequencing. Pharmacogenomics 15, 1117–1124 (2014).
17. Zhu, Y. et al. Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay. Clin. Chem. 52, 1033–1039 (2006).
18. Aekplakorn, W. et al. Prevalence and management of diabetes and associated risk factors by regions of Thailand. Third National Health Examination Survey 2004. Diabetes Care 30, 2007–2012 (2007).
19. Little S. Amplification-refactory mutation system (ARMS) analysis of point mutations. Curr. Protoc. Hum. Genet. Chapter 9, Unit 9.8, 1–12 (2001).
20. Medrano, R. F. & de Oliveira, C. A. Guidelines for the tetra-primer ARMS-PCR technique development. Mol. Biotechnol. 56, 599–608 (2014).
21. Stephens, M., Smith, N. J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989 (2001).
22. Stephens, M. & Scheet, P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76, 449–462 (2005).
23. Kukongviriyapan, V., Pravan, A., Tassaneyakul, W., Aemsa-Ard, J. & Waraibha, B. Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br. J. Clin. Pharm. 55, 276–281 (2003).
24. Selinski, S., Blazzkewicz, M., Ickstadt, K., Hengstler, J. G. & Golka, K. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch. Toxicol. 87, 2129–2139 (2013).
25. Suichichamanich, S. et al. NAT2: a genotype-based meta-analysis ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenet. Genom. 28, 167–176 (2018).